COLLEEN LINDLEAF: Open Payments
NPI 1417376781 · SPARKS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,005 in 99 payments from 18 companies in 2025. Trend: 2023 $38 · 2024 $1,267 · 2025 $2,005
Food & beverage: $2,005
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $401 |
| AstraZeneca Pharmaceuticals LP | 15 | $331 |
| Amgen Inc. | 12 | $220 |
| PFIZER INC. | 10 | $194 |
| Novo Nordisk Inc | 9 | $191 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $142 |
| GlaxoSmithKline, LLC. | 7 | $137 |
| Otsuka America Pharmaceutical, Inc. | 3 | $67 |
| Lilly USA, LLC | 3 | $61 |
| Exact Sciences Corporation | 3 | $49 |
Products named: VRAYLAR, BREZTRI, NURTEC ODT, CAPLYTA, OTEZLA, FARXIGA, Wegovy, KRYSTEXXA.
Industry payments across NV — which companies pay providers there.
